Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study

Journal of Clinical Medicine

Mohamed Hebbar¹  Gabrielle Feydel²  Bruno Pereira²  Caroline Pétorin³  Agnès Vimal-Baguet³  Sophie Trevis⁴  Vincent Pinon⁴  Valérie Lebrun-Ly⁵  Frédéric Thuillier⁵  Olivier Bouché⁶  Florian Slimano⁷  Floriane Huet-Penz⁸  Brigitte Monange⁹  KheirEddine Benmammar⁹  Vincent Bourgeois^1,10  Mohamed Ramdani^1,11  Sharif Kullab^1,12  Sergey Melnikov^1,13  Florent Genty^1,14  Ahmed Bedjaoui^1,15  Denis Péré-Vergé^1,16  Cécile Leyronnas^1,17  Thibault Mazard^1,18  David Tavan^1,19  Denis Pezet^2,20  Nicolas Kerckhove^2,21  David Balayssac^2,21  Marie Selvy^2,21  Jérôme Busserolles^2,22  Coralie Gonneau^2,22 

[1] CHRU Lille, Service Oncologie, F-59000 Lille, France;CHU Clermont-Ferrand, Délégation à la Recherche Clinique et à l’Innovation, F-63000 Clermont-Ferrand, France;CHU Clermont-Ferrand, Service Oncologie digestive, F-63000 Clermont-Ferrand, France;CHU Clermont-Ferrand, Service Pharmacie, Clermont-Ferrand, F-63000 Clermont-Ferrand, France;CHU Limoges, Service Oncologie, F-87042 Limoges, France;CHU Reims, Service Oncologie digestive, Université de Reims Champagne-Ardenne, F-51100 Reims, France;CHU Reims, Service Pharmacie, BioSpecT, EA n 7506, SFR CAP-Santé, Université de Reims Champagne-Ardenne, F-51100 Reims, France;Centre Hospitalier Alpes Leman, Service Gastro entérologie, F-74130 Contamine sur Arve, France;Centre Hospitalier Emile Roux, Service Oncologie, F-43000 Le Puy-en-Velay, France;Centre Hospitalier de Boulogne sur Mer, Service Oncologie digestive, F-62321 Boulogne-Sur-Mer, France;Centre Hospitalier de Béziers, Service Gastro-entérologie, F-34500 Béziers, France;Centre Hospitalier de Moulins Yzeure, Service Oncologie, F-03006 Moulins, France;Centre Hospitalier de Saint-Flour, Service Chirurgie générale et viscérale, F-15100 Saint-Flour, France;Centre Hospitalier de Vichy, Service Chirurgie digestive et viscérale, F-03200 Vichy, France;Centre hospitalier Intercommunal Les Hôpitaux du Léman, Service Gastro-entérologie, F-74203 Thonon les bains, France;Centre hospitalier Saint-Joseph Saint-Luc, Service Hépato-gastro-entérologie, F-69007 Lyon, France;Groupe Hospitalier Mutualiste de Grenoble, Service Oncologie, F-38000 Grenoble, France;IRCM, Inserm, Univ Montpellier, ICM, F-34298 Montpellier, France;Infirmerie protestante de Lyon, Service Gastro-entérologie, F-69300 Caluire et Cuire, France;Université Clermont Auvergne, INSERM U1071, M2iSH, USC-INRA 2018, CHU Clermont-Ferrand, F-63000 Clermont-Ferrand, France;Université Clermont Auvergne, INSERM U1107 NEURO-DOL, CHU Clermont-Ferrand, F-63000 Clermont-Ferrand, France;Université Clermont Auvergne, INSERM U1107 NEURO-DOL, F-63000 Clermont-Ferrand, France;

关键词: peripheral neuropathy;    oxaliplatin;    colorectal cancer;    health-related quality of life;    cancer survivors;   

DOI  :  10.3390/jcm9082400

来源: DOAJ

【 摘 要 】

(1) Background: Oxaliplatin is among the most neurotoxic anticancer drugs. Little data are available on the long-term prevalence and consequences of chemotherapy-induced peripheral neuropathy (CIPN), even though the third largest population of cancer survivors is made up of survivors of colorectal cancer. (2) Methods: A multicenter, cross-sectional study was conducted in 16 French centers to assess the prevalence of CIPN, as well as its consequences (neuropathic pain, anxiety, depression, and quality of life) in cancer survivors during the 5 years after the end of adjuvant oxaliplatin chemotherapy. (3) Results: Out of 406 patients, the prevalence of CIPN was 31.3% (95% confidence interval: 26.8–36.0). Little improvement in CIPN was found over the 5 years, and 36.5% of patients with CIPN also had neuropathic pain. CIPN was associated with anxiety, depression, and deterioration of quality of life. None of the patients with CIPN were treated with duloxetine (recommendation from American Society of Clinical Oncology), and only 3.2%, 1.6%, and 1.6% were treated with pregabalin, gabapentin, and amitriptyline, respectively. (4) Conclusions: Five years after the end of chemotherapy, a quarter of patients suffered from CIPN. The present study showed marked psychological distress and uncovered a failure in management in these patients.

【 授权许可】

Unknown